옵션 체인은 다양한 행사가격과 만기일에 대한 Castellum의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Castellum에 대한 시장 심리를 평가합니다..

Castellum (AMEX:CTM) 주식, 옵션 체인

Castellum

Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CWCO

GETY

SAIC

월요일(17일) 아침 미국 지수 선물이 하락세를 보이고 있는 가운데, 오늘 투자자 관심을 끌 수 있는 주식은 다음과 같다. 사이언스 어플리케이션, 게티 이미지, 카스텔럼, 콘솔리테이티드 워터 및 타운스퀘어

월요일 주목해야 할 주식: 사이언스 어플리케이션, 게티 이미지, 카스텔럼, 콘솔리테이티드 워터 및 타운스퀘어

Castellum Inc

CANTERRA MINERALS CORP by Canterra Minerals Corp.

Canterra Minerals Corp

CORPORATE TRAVEL MGMT LTD by Corporate Travel Management Ltd

Corporate Travel Management Ltd

CytomX Therapeutics Inc

<p>Truist Securities  analyst Richard Newitter   maintains Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Hold and lowers the price target from $90 to $82.</p>


Price Target

Analyst Ratings

GMED

Truist Securities Maintains Hold on Globus Medical, Lowers Price Target to $82

WIIM

XPEV

XPeng shares are trading lower after the company reported a Q4 Adj EPS miss.

<p>Guggenheim  analyst John Difucci   maintains Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Buy and raises the price target from $76 to $80.</p>


RBRK

Guggenheim Maintains Buy on Rubrik, Raises Price Target to $80

<p>Truist Securities  analyst Jailendra Singh   maintains Astrana Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTH#NASDAQ">ASTH</a>) with a Buy and lowers the price target from $50 to $46.</p>


ASTH

Truist Securities Maintains Buy on Astrana Health, Lowers Price Target to $46

<p>Earlier this month, Sycamore Partners agreed to acquire <strong>Walgreens Boots Alliance Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) for $11.45 per share <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">in cash at closing</a>. Shareholders are also eligible to receive up to $3 in cash per share from the future monetization of Walgreens&#8217; debt and equity interests in VillageMD, which includes the Village Medical, <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44182479/walgreens-stock-rises-as-company-inks-10b-deal-to-go-private" target="_blank" rel="noreferrer noopener">Summit Health and CityMD businesses</a>.</p>
<p>Soon after, <strong>Gary Black</strong>, managing partner at <strong>The Future Fund LLC</strong>, said, &#8220;I&#8217;ve talked before about how this company shouldn&#8217;t be public,&#8221; adding that the move is driven by its largest shareholder, executive chairman <strong>Stefano Pessina</strong>, who <a href="https://www.benzinga.com/markets/equities/25/03/44185847/gary-black-says-walgreens-is-a-company-that-shouldnt-be-public-cites-largest-shareholders-role-in-10-billion-sycamore-deal" target="_blank" rel="noreferrer noopener">holds a 16.9% stake</a>.</p>
<p>The Financial Times, citing sources, writes that Stefano Pessina plans to nearly double his stake in the company to about 30% as part of its acquisition.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43104245/justice-department-accuses-walgreens-of-violating-drug-laws-in-opioid-epidemic-ignored-red-flags-in-opioid-crisis" rel="noreferrer noopener">Justice Department Accuses Walgreens Of Violating Drug Laws In Opioid Epidemic, Ignored Red Flags In Opioid Crisis</a></strong></p>
<p>The move signals Pessina&#8217;s deepening involvement in the company&#8217;s future, potentially ahead of a breakup of its various business units.</p>
<p>The FT report <a href="https://www.ft.com/content/ef898a28-ed96-45b5-baae-7569b8b778a3" target="_blank" rel="noreferrer noopener">added</a> that the transaction will allow Walgreens to restructure the struggling pharmacy giant. Walgreens is currently in a 35-day window to evaluate competing offers.</p>
<p>Pessina&#8217;s existing stake is worth approximately $2.1 billion. The deal&#8217;s complex financing structure is expected to allow Sycamore to potentially separate Walgreens&#8217; various business units into independent entities, reviving the possibility of selling Boots after <a target="_blank" href="https://www.benzinga.com/m-a/22/01/24860084/bain-capital-reportedly-eyeing-boots-uk-takeover-from-walgreens-report" rel="noreferrer noopener">previous failed attempts</a>.</p>
<p>Walgreens&#8217; market value once exceeded $100 billion following the 2014 merger of Walgreens and Alliance Boots, a deal orchestrated by Pessina. However, the company&#8217;s value has since fallen below $10 billion, facing mounting challenges from online competitors and shifting consumer habits.</p>
<p>Sources indicate that Pessina played a key role in securing the Sycamore deal as he sought a solution to Walgreens&#8217; declining stock price.</p>
<p>In January,&nbsp;Walgreens reported first-quarter sales of $39.46 billion, up 7.5% year over year (+6.9% on constant currency), beating the&nbsp;consensus of $37.28 billion, reflecting sales growth <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/42912519/walgreens-boots-alliance-stock-jumps-on-better-than-expected-q1-earnings-sticks-to-annual-profit-forecast" rel="noreferrer noopener">across all segments</a>.</p>
<p>Analysts estimate Walgreens&#8217; second quarter 2025 adjusted EPS of 53 cents, with sales of $37.9 billion. Wall Street forecasts 2025 adjusted EPS of $1.61 and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $151.6 billion</a>.</p>
<p><strong>Price Action:</strong> WBA stock is down 0.04% at $11.26&nbsp;at the last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/03/44375647/canadian-cannabis-sndl-achieves-break-even-free-cash-flow-for-2024" target="_blank" rel="noreferrer noopener">Canadian Cannabis SNDL Achieves Break-Even Free Cash Flow For 2024</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Large Cap

Health Care

General

Walgreens' Executive Chair Stefano Pessina Seeks To Strengthen Control With Nearly Double Stake

Regencell Bioscience Shares Halted On Circuit Breaker To The Downside, Stock Now Up 27.5%

<p>Guggenheim  analyst Michael Schmidt   downgrades Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Buy to Neutral and maintains the price target from $92 to $92.</p>


Downgrades

INCY

Guggenheim Downgrades Incyte to Neutral, Maintains Price Target to $92

<p>Truist Securities  analyst Ki Bin Kim   maintains Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) with a Hold and lowers the price target from $316 to $310.</p>


Truist Securities Maintains Hold on Public Storage, Lowers Price Target to $310

<p>Compass Point  analyst Casey Alexander   maintains TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) with a Neutral and lowers the price target from $8 to $7.25.</p>


TPVG

Compass Point Maintains Neutral on TriplePoint Venture Gwth, Lowers Price Target to $7.25

<p>Truist Securities  analyst Ki Bin Kim   maintains EPR Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>) with a Hold and raises the price target from $46 to $51.</p>


Truist Securities Maintains Hold on EPR Props, Raises Price Target to $51

<p>Guggenheim  analyst Curry Baker   initiates coverage on Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) with a Buy rating and announces Price Target of $12.</p>


Initiation

GENI

Guggenheim Initiates Coverage On Genius Sports with Buy Rating, Announces Price Target of $12

<p>Deep-pocketed investors have adopted a bearish approach towards Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MU usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Micron Technology. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 13% leaning bullish and 80% bearish. Among these notable options, 8 are puts, totaling $565,394, and 7 are calls, amounting to $354,723.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70.0 to $120.0 for Micron Technology over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Micron Technology's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Micron Technology's substantial trades, within a strike price spectrum from $70.0 to $120.0 over the preceding 30 days.</p>
<h3>Micron Technology 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742306474_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.35</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$99.00</td>
<td>$210.8K</td>
<td>607</td>
<td align="right">543</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.85</td>
<td>$4.7</td>
<td>$4.65</td>
<td>$100.00</td>
<td>$93.6K</td>
<td>12.9K</td>
<td align="right">217</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$40.2</td>
<td>$39.8</td>
<td>$39.8</td>
<td>$70.00</td>
<td>$79.6K</td>
<td>865</td>
<td align="right">0</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$8.5</td>
<td>$8.4</td>
<td>$8.4</td>
<td>$100.00</td>
<td>$77.2K</td>
<td>14.1K</td>
<td align="right">110</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$24.1</td>
<td>$23.1</td>
<td>$23.9</td>
<td>$100.00</td>
<td>$69.3K</td>
<td>105</td>
<td align="right">29</td>
</tr>
</tbody>
</table>
</p>
<h3>About Micron Technology</h3>
<p>Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.</p>
<p>After a thorough review of the options trading surrounding Micron Technology, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Micron Technology</h3>
<ul>
<li>With a volume of 1,886,364, the price of MU is down -1.9% at $101.15. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 2 days.</li>
</ul>
<h3>What The Experts Say On Micron Technology</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $128.33.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Micron Technology with a target price of $130.<br />
&#x2A; In a cautious move, an analyst from Wedbush downgraded its rating to Outperform, setting a price target of $125.<br />
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Micron Technology, which currently sits at a price target of $130. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Micron Technology options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Micron Technology's Options Frenzy: What You Need to Know

<p>Deep-pocketed investors have adopted a bullish approach towards XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in XPEV usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for XPeng. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 66% leaning bullish and 11% bearish. Among these notable options, 4 are puts, totaling $150,960, and 5 are calls, amounting to $276,030.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $35.0 for XPeng over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in XPeng's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to XPeng's substantial trades, within a strike price spectrum from $10.0 to $35.0 over the preceding 30 days.</p>
<h3>XPeng Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742306468_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>XPEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.1</td>
<td>$2.73</td>
<td>$3.0</td>
<td>$35.00</td>
<td>$114.0K</td>
<td>6.6K</td>
<td align="right">404</td>
</tr>
<tr>
<td>XPEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.9</td>
<td>$5.35</td>
<td>$5.83</td>
<td>$18.00</td>
<td>$58.2K</td>
<td>277</td>
<td align="right">100</td>
</tr>
<tr>
<td>XPEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$3.45</td>
<td>$3.15</td>
<td>$3.3</td>
<td>$19.00</td>
<td>$46.2K</td>
<td>1.0K</td>
<td align="right">145</td>
</tr>
<tr>
<td>XPEV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$4.6</td>
<td>$4.45</td>
<td>$4.5</td>
<td>$22.00</td>
<td>$45.0K</td>
<td>902</td>
<td align="right">337</td>
</tr>
<tr>
<td>XPEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/17/25</td>
<td>$4.5</td>
<td>$4.15</td>
<td>$4.31</td>
<td>$22.00</td>
<td>$43.0K</td>
<td>902</td>
<td align="right">227</td>
</tr>
</tbody>
</table>
</p>
<h3>About XPeng</h3>
<p>Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 141,000 EVs in 2023, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.</p>
<h3>XPeng's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 6,931,461, the XPEV's price is down by -8.73%, now at $22.41. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 0 days.</li>
</ul>
<h3>Professional Analyst Ratings for XPeng</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $23.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Showing optimism, an analyst from UBS upgrades its rating to Neutral with a revised price target of $18.<br />
&#x2A; An analyst from Citigroup has elevated its stance to Buy, setting a new price target at $29. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest XPeng options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


A Closer Look at XPeng's Options Market Dynamics

<p>In the preceding three months, 5 analysts have released ratings for Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend is evident, with the current average reflecting a 6.32% increase from the previous average price target of $91.80.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742306466_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Globus Medical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$97.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Globus Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Globus Medical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Globus Medical's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Globus Medical's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GMED/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Globus Medical analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Globus Medical</h2>
<p>Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.</p>
<h3>Understanding the Numbers: Globus Medical's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Globus Medical's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>6.61%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Globus Medical's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>4.03%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Globus Medical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>0.64%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Globus Medical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.51%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Globus Medical's debt-to-equity ratio is below the industry average at <strong>0.13</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Globus Medical: 5 Analysts Share Their Views

<p>Deep-pocketed investors have adopted a bearish approach towards Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in COST usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Costco Wholesale. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 23% leaning bullish and 53% bearish. Among these notable options, 7 are puts, totaling $461,953, and 6 are calls, amounting to $282,495.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $500.0 to $1460.0 for Costco Wholesale during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Costco Wholesale stands at 174.5, with a total volume reaching 230.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Costco Wholesale, situated within the strike price corridor from $500.0 to $1460.0, throughout the last 30 days.</p>
<h3>Costco Wholesale Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742306462_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>COST</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$24.5</td>
<td>$23.35</td>
<td>$24.5</td>
<td>$820.00</td>
<td>$98.0K</td>
<td align="right">341</td>
<td align="right">80</td>
</tr>
<tr>
<td>COST</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$25.0</td>
<td>$24.0</td>
<td>$24.0</td>
<td>$820.00</td>
<td>$96.0K</td>
<td align="right">341</td>
<td align="right">0</td>
</tr>
<tr>
<td>COST</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$15.3</td>
<td>$15.3</td>
<td>$15.3</td>
<td>$890.00</td>
<td>$76.5K</td>
<td align="right">658</td>
<td align="right">52</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$251.0</td>
<td>$249.0</td>
<td>$251.0</td>
<td>$660.00</td>
<td>$75.3K</td>
<td align="right">24</td>
<td align="right">3</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$257.8</td>
<td>$250.95</td>
<td>$250.95</td>
<td>$740.00</td>
<td>$75.2K</td>
<td align="right">19</td>
<td align="right">3</td>
</tr>
</tbody>
</table>
</p>
<h3>About Costco Wholesale</h3>
<p>Costco operates a membership-based, no-frills retail model predicated on offering a select product assortment in bulk quantities at bargain prices. The firm avoids maintaining costly product displays by keeping inventory on pallets and limits distribution expenses by storing its inventory at point of sale in the warehouse. Given its frugal cost structure, the firm is able to price its merchandise below that of competing retailers, driving high sales volume per warehouse and generating strong profits on thin margins. Costco operates over 600 warehouses in the United States and has over 60% share in the domestic warehouse club industry. Internationally, Costco operates another 280 warehouses, primarily in Canada, Mexico, Japan, and the UK.</p>
<p>Following our analysis of the options activities associated with Costco Wholesale, we pivot to a closer look at the company's own performance.</p>
<h3>Costco Wholesale's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 139,383, the COST's price is down by -1.21%, now at $905.51. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 72 days.</li>
</ul>
<h3>What The Experts Say On Costco Wholesale</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $1085.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Costco Wholesale, targeting a price of $995.<br />
&#x2A; Maintaining their stance, an analyst from Loop Capital continues to hold a Buy rating for Costco Wholesale, targeting a price of $1135.<br />
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on Costco Wholesale, maintaining a target price of $1070.<br />
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for Costco Wholesale, targeting a price of $1125.<br />
&#x2A; An analyst from Telsey Advisory Group persists with their Outperform rating on Costco Wholesale, maintaining a target price of $1100. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Costco Wholesale options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


COST

Costco Wholesale's Options Frenzy: What You Need to Know

<p>Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $19.6, a high estimate of $28.00, and a low estimate of $16.00. Observing a downward trend, the current average is 35.1% lower than the prior average price target of $30.20. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742306455_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Staar Surgical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$17.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Staar Surgical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Staar Surgical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Staar Surgical's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/STAA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Staar Surgical analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know Staar Surgical Better</h2>
<p>Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.</p>
<h3>Unraveling the Financial Story of Staar Surgical</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Staar Surgical's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-35.82%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Staar Surgical's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-69.92%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Staar Surgical's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-8.29%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Staar Surgical's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-6.54%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Staar Surgical's debt-to-equity ratio is below the industry average at <strong>0.1</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


STAA

Analyst Expectations For Staar Surgical's Future

<p><strong><a href="https://www.benzinga.com/news/24/04/38510070/apple-co-founder-steve-wozniak-reveals-his-unique-obsession-with-this-weird-object-many-of-the-best">Steve Wozniak</a></strong> and <strong>Elon Musk</strong> should, in theory, have a lot in common–two tech visionaries, each revolutionizing their respective industries. But while Apple built its empire on making things easier for users, Tesla, in Wozniak&#8217;s eyes, has been doing the exact opposite. Once an enthusiastic Tesla owner, the Apple co-founder has grown disillusioned with the company and its CEO, and now, he says, Musk has personally shut him out.</p>
<p>Wozniak says his X account was blocked after years of <a href="https://finance.yahoo.com/news/elon-musk-jokingly-refers-apple-190015107.html">publicly criticizing Musk</a>. He believes his outspoken remarks about failed promises and questionable business practices led to the sudden restriction—despite never violating platform rules.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a></strong><strong> Here&#8217;s what Americans think you need to be considered wealthy.</strong></li>
<li><strong>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"><strong> </strong><strong>they all believe in one platform that offers a 7-9% target yield with monthly dividends</strong></a></strong></li>
</ul>
<p>In a <a href="https://bsky.app/profile/stevewoz.bsky.social/post/3liauvck55c2f">post on Bluesky</a> last month, Wozniak wrote:</p>
<p>"Over years, I have a few times called Musk a liar (across the country by 2016, then 2017) and thief (money for upgrades), on national TV even. Maybe that's why my Twitter account has been blocked for a few months despite violating no rules. I can't get it fixed."</p>
<p>Just days later, during a <a href="https://youtube.com/shorts/Ochn8GPj11E?si=O210E7ELtk57hQEC">CNBC interview</a>, Wozniak doubled down, recalling how Musk repeatedly promised Tesla's self-driving technology would be ready by 2016, then pushed it to 2017. He accused Musk of misleading customers and taking their money for software that never delivered.</p>
<p>"He lied to us about driving himself across the country by the end of 2016 and then by the end of 2017," Wozniak said. "And he got money from us—stole money from us—to try to upgrade to the one that would do it, when they wouldn't."</p>
<p><strong>Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks"><strong>See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</strong></a></strong></p>
<p>He described his frustration over losing access to X, saying he went through all verification steps but couldn't regain control of his account.</p>
<p>"I follow every single step to prove that I'm real, really who I am, and I can't get it unblocked," he said. "I don't know if they're doing that deliberately, but I never really posted on X, I never ever violated any rule or anything. But maybe it's because I was on the <a href="https://www.benzinga.com/25/03/44160018/apple-co-founder-steve-wozniak-blasts-doges-mass-firings-says-musk-led-cuts-are-like-using-a-sledgehammer-instead-of-a-scalpel">wrong side of Elon</a>."</p>
<p>In 2014, Wozniak was one of Tesla's biggest fans. In an <a href="https://www.nbcnews.com/tech/innovation/apple-co-founder-steve-wozniak-loves-tesla-oculus-rift-n245531">interview with NBC News</a>, he spoke about the Tesla he and his wife had purchased, saying, "We love it more than any other car we have."</p>
<p><strong><em>See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it"><strong><em>Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</em></strong></a></em></strong></p>
<p>But that admiration didn't last. Over time, he's soured on its technology, calling Tesla's user interface "the worst in the world." He described how updates have made basic functions harder, like accessing the glove box or finding turn signals on the yoke steering wheel.</p>
<p>"Nothing makes sense in that car intuitively," he said. "You have to go searching in menus until you stumble into finding it—it's horrible."</p>
<p>Wozniak's account remains blocked, and he claims he hasn't received an explanation. Whether intentional or not, it's clear he believes his public criticism of Musk cost him access to one of the world's largest social media platforms.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"><strong> Here's how to turn it into lasting wealth</strong></a></strong></li>
<li><strong>Dogecoin millionaires are increasing –<a href="https://www.benzinga.com/money/dogecoin-millionaires"><strong> </strong><strong>investors with $1M+ in DOGE revealed!</strong></a></strong></li>
</ul>


Personal Finance

'I Was on The Wrong Side of Elon' — Apple Co-Founder Steve Wozniak Says His X Account Got Blocked After Publicly Calling Musk a 'Liar' and 'Thief'

<p>In the preceding three months, 6 analysts have released ratings for Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Bio-Techne, revealing an average target of $78.83, a high estimate of $90.00, and a low estimate of $68.00. A decline of 5.02% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742306448_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of Bio-Techne among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Markowitz</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$90.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Bio-Techne. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bio-Techne compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Bio-Techne's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Bio-Techne's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TECH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Bio-Techne analyst ratings.</strong></a></p>
<h2>All You Need to Know About Bio-Techne</h2>
<p>Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.</p>
<h3>Key Indicators: Bio-Techne's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Bio-Techne's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>8.96%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Bio-Techne's net margin is impressive, surpassing industry averages. With a net margin of <strong>11.75%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.65%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Bio-Techne's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.29%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Bio-Techne's debt-to-equity ratio is below the industry average at <strong>0.19</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TECH

6 Analysts Assess Bio-Techne: What You Need To Know

<p>Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Lucid Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) in the last three months.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $3.0, along with a high estimate of $5.00 and a low estimate of $1.00. Experiencing a 14.29% decline, the current average is now lower than the previous average price target of $3.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742306436_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Lucid Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$3.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$3.00</td>
<td>$3.50</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$1.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Lucid Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Lucid Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Lucid Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Lucid Group's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LCID/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Lucid Group analyst ratings.</strong></a></p>
<h2>Discovering Lucid Group: A Closer Look</h2>
<p>Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations and through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.</p>
<h3>A Deep Dive into Lucid Group's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Lucid Group showcased positive performance, achieving a revenue growth rate of <strong>49.2%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-271.63%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Lucid Group's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-19.43%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Lucid Group's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-7.02%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Lucid Group's debt-to-equity ratio is below the industry average. With a ratio of <b>0.64</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LCID

What Analysts Are Saying About Lucid Group Stock

<p>Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $252.62, a high estimate of $261.00, and a low estimate of $242.00. Observing a 10.17% increase, the current average has risen from the previous average price target of $229.29. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742306427_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive Cheniere Energy is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Mosca</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$254.00</td>
<td>$248.00</td>
</tr>
<tr>
<td>Brandon Bingham</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$254.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Benjamin Nolan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$255.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Fotis Giannakoulis</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Brandon Bingham</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$247.00</td>
<td>$242.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$253.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Holly Stewart</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$242.00</td>
<td>-</td>
</tr>
<tr>
<td>John Mackay</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$261.00</td>
<td>$234.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cheniere Energy. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Cheniere Energy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Cheniere Energy's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Cheniere Energy's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LNG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Cheniere Energy analyst ratings.</strong></a></p>
<h2>About Cheniere Energy</h2>
<p>Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.</p>
<h3>Unraveling the Financial Story of Cheniere Energy</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Cheniere Energy's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-8.02%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>22.02%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Cheniere Energy's ROE excels beyond industry benchmarks, reaching <strong>18.09%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Cheniere Energy's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.25%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Cheniere Energy's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>4.49</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: Cheniere Energy In The Eyes Of 8 Experts

Press Releases

Castellum Announces Pricing of $3.7 Million Public Offering of Common Stock

Castellum, Inc.'s SBA Protégés Successfully Onboard to SeaPort-NxG Contract

Contracts

Castellum Announces the Award of a $3.2 million Contract to its Specialty Systems, Inc. Subsidiary

Castellum, Inc. Announces Its GTMR Subsidiary Has Been Selected as a SCI MAC Vendor

Castellum, Inc. Announces 2024 Unaudited Financial Results

Castellum, Inc. Announces the Award of a $103.3 million Contract to its GTMR Subsidiary

Management

Castellum, Inc. Hires Tanya Bassett as Vice President of Business Development and Capture Management; Reinforces Strategic Commitment to Organic Growth

Castellum Announces Proposed Public Offering of Common Stock and Warrants

Castellum Announces Pricing of $4.5 Million Public Offering of Common Stock and Warrants

Castellum, Inc.'s Subsidiary GTMR Achieves CMMI Level 3 Appraisal

Accenture plc Class A Ordinary Shares (Ireland)

Accenture

ASGN

Alpha Technology Group Limited - Class A Ordinary Shares

Alpha Technology Group

BigBear.ai Hldgs

CI&T

Cognizant Technology Solutions Corporation - Class A Common Stock

Cognizant Tech Solns

Endava plc American Depositary Shares (each representing one Class A Ordinary Share)

Comments

Castellum

Castellum (CTM) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌